VT-1598_product_DataBase

Bioactivity	VT-1598 is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 shows anti-fungal activity against Candida auris[1][2].
Invitro	VT-1598 (0.015-8 μg/mL; 24 h) 对临床念珠菌 (C. auris) 具有体外抑制活性[1]。VT-1598 (0.03125-0.125 μg/mL; 24 h) 对临床念珠菌 (C. auris) 的体外生长有显著抑制作用[2]。 Cell Viability Assay[1] Cell Line:
In Vivo	VT-1598 (口服灌胃; 5, 15, and 50 mg/kg; 每天一次; 7 天) 处理小鼠，使其呈剂量依赖性的生存优势，VT-1598 还剂量依赖性降低小鼠体内的真菌负荷量[1]。VT-1598 (口服灌胃; 3.2, 8, and 20 mg/kg; 每天一次; 4 天) 在感染白色念珠菌 (C. albicans) 的 Act1 缺陷小鼠的血浆和舌中大量存在[2]。 Animal Model:
Name	VT-1598
CAS	2089320-99-8
Formula	C31H20F4N6O2
Molar Mass	584.52
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Nathan P Wiederhold, et al. The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e02233-18. [2]. Timothy J Break, et al. VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice. J Antimicrob Chemother. 2018 Aug 1;73(8):2089-2094.

PeptideDB